Candel Therapeutics (CADL) Non-Current Debt (2021 - 2025)

Candel Therapeutics has disclosed Non-Current Debt across 5 years of filings, most recently posting $1.0 million for Q4 2025.

• Non-Current Debt for Q4 2025 came in at $1.0 million, up 15.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (up 15.86% YoY), and the FY2025 annual result was $1.0 million, up 15.86% from the prior year.
• Non-Current Debt came in at $1.0 million for Q4 2025 at Candel Therapeutics, up from $904000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.2 million in Q4 2022 to a low of $560000.0 in Q4 2021.
• The 5-year median for Non-Current Debt is $1.0 million (2025), against an average of $7.8 million.
• Across the five-year window, Non-Current Debt soared 3507.5% in 2022 and plunged 95.15% in 2024, its largest moves.
• Candel Therapeutics' Non-Current Debt stood at $560000.0 in 2021, then jumped by 3507.5% to $20.2 million in 2022, then tumbled by 42.42% to $11.6 million in 2023, then slumped by 92.52% to $870000.0 in 2024, then increased by 15.86% to $1.0 million in 2025.
• The last three Non-Current Debt figures came in at $1.0 million (Q4 2025), $904000.0 (Q1 2025), and $870000.0 (Q4 2024), per Business Quant data.